Advertisement
INCY vs REGN
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- INCY reported Q4 2025 revenue growth of 28% to $1.51 billion, driven by Jakafi and Opzelura, but shares dipped post-earnings due to EPS miss.
- REGN trades at a higher market cap of $83B with stable performance, bolstered by Dupixent approvals and Eylea growth.
- Over the past year, INCY delivered 41.88% returns vs. REGN's 17.22%, reflecting stronger relative momentum for the smaller cap.
- Recent weeks show both stocks fluctuating around recent highs, with INCY near $99 and REGN near $788 amid pipeline advancements.
- Analyst targets suggest upside: INCY at $107 (8% potential), REGN at $871 (10% potential).
- Biotech peers highlight REGN's profitability edge, while INCY emphasizes pipeline diversification.
Introduction
Incyte Corporation (INCY) and Regeneron Pharmaceuticals (REGN) represent key players in the biotechnology sector, focusing on oncology, hematology, and immunology therapeutics. This stock comparison evaluates their recent market performance, pipeline progress, and relative positioning amid evolving biotech sentiment. Traders seeking momentum opportunities and investors eyeing diversified growth profiles may find value in contrasting INCY's smaller-cap agility with REGN's established scale. With both advancing clinical milestones in recent market activity, understanding their contrasts aids informed relative performance assessments.
INCY Overview and Recent Performance
Incyte Corporation (INCY), a biopharmaceutical firm headquartered in Wilmington, Delaware, specializes in discovering, developing, and commercializing therapeutics for oncology, hematology, and dermatology. Flagship products include Jakafi for myelofibrosis and polycythemia vera, and Opzelura for atopic dermatitis and vitiligo. In recent market activity, INCY shares traded around $99, within a 52-week range of $53.56-$112.29, reflecting a year-to-date return of 0.09% and 41.88% over one year. Q4 2025 revenue surged 28% to $1.51 billion, fueled by Jakafi and Opzelura sales, though an EPS miss at $1.80 versus $1.92 expected led to initial pressure. Positive catalysts include positive topline from the Phase 3 frontMIND trial for tafasitamab in first-line DLBCL and CHMP opinion for Zynyz in anal cancer, signaling pipeline diversification beyond Jakafi. Recent weeks saw fluctuations from $109 peaks to stabilization near $99, influenced by earnings digestion and oncology sentiment.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN), based in Tarrytown, New York, develops biologics for serious diseases, with blockbusters like Eylea for retinal conditions and Dupixent (co-commercialized with Sanofi) for allergic diseases. Shares recently hovered near $788, in a 52-week range of $476.49-$821.11, posting YTD gains of 2.15% and 17.22% annually. Recent activity featured Dupixent's CHMP recommendation for pediatric urticaria and U.S. approval for allergic fungal rhinosinusitis, alongside immunology pipeline highlights at AAAAI. Eylea HD uptake supports stability, with Q4 revenue at $3.88 billion. Price trends in recent weeks showed upward momentum to $803 mid-February before settling around $787, driven by approvals and analyst upgrades amid broader biotech positioning. Market sentiment reflects confidence in REGN's profitability and growth in respiratory and rare diseases.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top-performing AI trading bots from hundreds available, each scanning thousands of tickers across diverse strategies, timeframes, and styles like trend following, swing trading, and hedging. Only those excelling in current volatility—such as semiconductors, aerospace, biotech ETFs, and small caps—earn a spot, with stats like annualized returns up to +237%, win rates of 70-95%, and profit factors reaching 25+. Examples include Biotechnology BIB (15min AI/ML) at +24.80% annualized with 94.92% win rate, and broader bots like XAR/ITA/SOXL at +116.56%. These bots adapt via machine learning on 5-60min intervals, offering real-time signals for copy trading. Explore Trending AI Robots to align with market conditions.
Head-to-Head Comparison
INCY and REGN both anchor in biotech but diverge in scale and focus: INCY's $20B market cap emphasizes small-molecule oncology/hematology diversification amid Jakafi patent cliffs, while REGN's $83B stature leverages biologics in eye diseases and immunology via Dupixent royalties. Growth drivers contrast INCY's 21% annual revenue rise and 14 planned pivots with REGN's mature Eylea stability and 18 Phase III studies. Recent momentum favors INCY's 42% one-year outperformance versus REGN's steadier path. Risks include INCY's earnings volatility and competition in DLBCL, versus REGN's biosimilar threats to Eylea. Sector exposure overlaps in oncology but REGN adds allergy breadth; sentiment tilts toward REGN's profitability (31% margins) over INCY's growth trajectory.
Tickeron AI Verdict
Tickeron’s AI currently leans toward REGN for its trend consistency, superior stability, and catalysts like Dupixent expansions amid biotech volatility. While INCY shows stronger recent relative performance and pipeline momentum, REGN's larger scale and profitability position it probabilistically better for sustained outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and REGN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 6 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).
- INCY’s TA Score: 6 bullish, 2 bearish.
- REGN’s TA Score: 3 bullish, 5 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.70% price change this week, while REGN (@Biotechnology) price change was +1.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.57%. For the same industry, the average monthly price growth was +5.22%, and the average quarterly price growth was +13.90%.
Reported Earning Dates
INCY is expected to report earnings on Aug 04, 2026.
REGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+1.57% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INCY | REGN | INCY / REGN | |
| Capitalization | 19.7B | 74.9B | 26% |
| EBITDA | 1.87B | 5.75B | 33% |
| Gain YTD | -0.213 | -7.271 | 3% |
| P/E Ratio | 13.92 | 17.45 | 80% |
| Revenue | 5.36B | 14.9B | 36% |
| Total Cash | 4.02B | 8.75B | 46% |
| Total Debt | 39.4M | 2.71B | 1% |
INCY | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 70 | 77 | |
SMR RATING 1..100 | 32 | 58 | |
PRICE GROWTH RATING 1..100 | 50 | 57 | |
P/E GROWTH RATING 1..100 | 100 | 30 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for INCY (68). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.
INCY's Profit vs Risk Rating (70) in the Biotechnology industry is in the same range as REGN (77). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is in the same range as REGN (58). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.
INCY's Price Growth Rating (50) in the Biotechnology industry is in the same range as REGN (57). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for INCY (100). This means that REGN’s stock grew significantly faster than INCY’s over the last 12 months.
| INCY | REGN | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 76% |
| Stochastic ODDS (%) | 4 days ago 57% | 4 days ago 71% |
| Momentum ODDS (%) | 4 days ago 64% | 4 days ago 58% |
| MACD ODDS (%) | N/A | 4 days ago 49% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 65% |
| TrendMonth ODDS (%) | 4 days ago 60% | 4 days ago 60% |
| Advances ODDS (%) | 6 days ago 62% | N/A |
| Declines ODDS (%) | 18 days ago 59% | 13 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 59% | 4 days ago 60% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 63% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PRXV | 32.98 | 0.21 | +0.65% |
| Praxis Impact Large Cap Value ETF | |||
| GBTC | 62.31 | 0.03 | +0.05% |
| Grayscale Bitcoin Trust ETF | |||
| IBMQ | 25.48 | N/A | N/A |
| iShares iBonds Dec 2028 Term Muni Bd ETF | |||
| RWM | 14.20 | -0.10 | -0.70% |
| ProShares Short Russell2000 | |||
| LTL | 27.29 | -0.27 | -0.97% |
| ProShares Ultra Communication Services | |||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with SMMT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then SMMT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | +0.82% | ||
| SMMT - REGN | 43% Loosely correlated | +5.42% | ||
| ARQT - REGN | 39% Loosely correlated | +2.47% | ||
| IDYA - REGN | 35% Loosely correlated | +0.28% | ||
| GMAB - REGN | 34% Loosely correlated | -2.33% | ||
| INCY - REGN | 33% Poorly correlated | +0.81% | ||
More | ||||